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Abstract
Background: Acquired myasthenia gravis (MG) is a rare antibody-mediated autoimmune disease caused by impaired
neuromuscular transmission, leading to abnormal muscle fatigability. The aetiology is complex, including genetic risk factors
of the human leukocyte antigen (HLA) complex and unknown environmental factors. Although associations between the
HLA complex and MG are well established, not all involved components of the HLA predisposition to this heterogeneous
disease have been revealed. Well-powered and comprehensive HLA analyses of subgroups in MG are warranted, especially
in late onset MG.
Methodology/Principal Findings: This case-control association study is of a large population-based Norwegian cohort of
369 MG patients and 651 healthy controls. We performed comprehensive genotyping of four classical HLA loci (HLA-A, -B, -C
and -DRB1) and showed that the DRB1*15:01 allele conferred the strongest risk in late onset MG (LOMG; onset $60years)
(OR 2.38, pc7.4610
25). DRB1*13:01 was found to be a protective allele for both early onset MG (EOMG) and LOMG (OR 0.31,
pc 4.71610
24), a finding not previously described. No significant association was found to the DRB1*07:01 allele (pnc = 0.18)
in a subset of nonthymomatous anti-titin antibody positive LOMG as reported by others. HLA-B*08 was mapped to give the
strongest contribution to EOMG, supporting previous studies.
Conclusion: The results from this study provide important new information concerning the susceptibility of HLA alleles in
Caucasian MG, with highlights on DRB1*15:01 as being a major risk allele in LOMG.
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Introduction
Acquired myasthenia gravis (MG) is a rare autoimmune
neuromuscular disease with an overall prevalence of 10–20 per
100 000 [1]. MG is caused by impaired neuromuscular trans-
mission leading to abnormal muscle fatigability affecting in some
cases only the eye muscles (ocular MG), but in most cases several
muscles groups (generalised MG) [2,3]. The muscle fatigability is
mediated by pathogenic autoantibodies against the muscle
acetylcholine receptors (AChR-abs) detectable in the majority of
patients (80–85%) [4]. Among the remaining patients without
AChR-abs, 10–50% have antibodies to the muscle specific kinase
(MuSK) [5,6]. Recent studies have revealed that some might have
low-affinity AChR-abs, to date not detectable with routinely used
assays [7]. MG is characterized by remarkable heterogeneity,
including degree of thymus involvement and clinical presentation
like age at onset, disease severity and response to treatment [8].
The two major subgroups of patients are currently classified
according to age at onset: early onset MG (EOMG) and late onset
MG (LOMG). Age-cut off between these subgroups differs
between studies, ranging from 40 and 50 years at onset [9].
Another MG subgroup consists of patients with thymoma, which is
a paraneoplastic condition that occurs in 10–15% of all MG
patients and at any age [10]. Typically, EOMG shows thymus
hyperplasia and a strong female preponderance, while LOMG has
a male predominance and normal or atrophic thymus findings [8].
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LOMG is considered to be a more heterogeneous group than
EOMG. Some LOMG patients with age at onset between 40 and
50 years might represent EOMG with delayed onset [11,12]. A
subset of LOMG with detectable anti-titin antibodies (ATA) in
about 50% of the cases has also been reported, whereas ATA is
rarely found in EOMG [13,14]. Thus, to define a more
homogeneous group of LOMG, some clinical studies have used
60 years as age cut-off [15].
The aetiology of MG is complex and explained by a combina-
tion of genetic and unknown environmental factors [16]. The
genetic associations found in MG are several [17], and the most
important genetic risk factor is conferred to the human leukocyte
antigen (HLA) complex, as it is for many other autoimmune
diseases [18]. The first genetic studies of Caucasian MG showed
different associations to HLA alleles in both Class I (HLA-A, -B
and -C) and Class II (HLA-DRB1 and -DQB1), suggesting that the
heterogeneity of the disease may be explained partly on a genetic
basis [19–26]. An increased prevalence of the extended HLA A1-
B8-DR3 haplotype (also called the ancestral haplotype AH 8.1)
was found in patients with disease onset before the age of 40 years
i.e. EOMG, while an association with the HLA-B7-DR2
haplotype was reported in patients with onset age older than 40
years i.e. LOMG. MG with thymoma has consistently not shown
associations with HLA, except for a recent study reporting
a positive association with the HLA-A locus [27].
Three decades ago, Compston and colleagues first addressed the
different HLA genetic risk factors in EOMG and LOMG [23].
Since then, several studies have aimed to find the diseases
causative locus in MG subgroups (Figure 1) [28–36], but the strong
linkage disequilibrium (LD) in the HLA complex has long
hampered this search [28,29,37]. There has also been lack of
comprehensive HLA genotyping in population-based studies
comprising a sufficient number of both EOMG and LOMG
cases. The association with haplotype AH 8.1 in EOMG has been
largely consistent, and several studies have suggested HLA-B8 as
the predominant associated allele in this haplotype [30–32,35]. In
LOMG, the search for HLA risk alleles has been more
challenging, partly because of limited sample sizes and the clinical
heterogeneity within the subgroup. Although previous studies have
pointed out HLA-B7 and/or DR2 as associated loci [23,30,37]
and recently DR7 in a subset of nonthymomatous anti-titin
antibodies (ATA) positive LOMG [35], definite HLA genetic risk
factors for LOMG have not yet been established.
Based on this background, this study aimed to investigate a large
Norwegian MG population with well defined subgroups of
patients, and carry out comprehensive genotyping of HLA Class
I and II loci in order to better characterise the genetic risk factors
in MG subgroups In particular, we aimed to focus on finding the
major HLA risk allele in the LOMG subgroup.
Materials and Methods
Patients and Controls
In this population-based study, subjects with acquired MG ($16
years) were collected from all neurological departments and clinics
with private neurologists in Norway in the period of 1.1.2005–
1.11.2009. The inclusion criteria for acquired MG were at least ‘‘1
and 2’’ or ‘‘1 and 3’’ of the following criteria: 1) clinical MG, 2)
neurophysiologic evidence consistent with MG (decrement .10%
at 3 Hz after repetitive motor nerve stimulation, increased jitter on
single-fibre electromyogram [38] or both), and 3) elevated level of
acetylcholine receptor (AChR) antibodies or muscle specific kinase
(MuSK) antibodies. Exclusion criteria were age ,16 years, and
lack of both criteria 2 and 3, mentioned above.
A total of 532 MG patients were identified, and 404 (76%)
consented to participate in the genetic study by donating blood
samples for DNA preparation. Retrospectively, clinical informa-
tion from the study participants (n = 404) was obtained from the
patient’s medical records, and antibodies titres were checked with
the AChR-abs Register at the Department of Neurology, Hauke-
land University Hospital, and Bergen, Norway. Clinical in-
formation registered include: age at disease onset, AChR-abs,
concomitant immune-mediated diseases, thymectomy, thymus
histopathology and highest score of disease severity according to
revised classification proposed by the Task Force of The Medical
Advisory Board of the Myasthenia Gravis Foundation of America
(MGFA) [39].
To minimize possible population stratification, all MG subjects
included in the HLA case-control study were ethnically Norwe-
gian, as were the control subjects. Hence, 26 non-ethnic
Norwegian MG patients were excluded, among whom one was
MuSK positive. Only one additional MuSK positive patient was
recognised and also excluded. Altogether, 378 unrelated Norwe-
gian Caucasian MG patients were included in the HLA case-
control study.
The control samples (n = 651, female: male ratio 1.9) were
randomly selected among healthy Norwegian bone marrow
donors recruited through the Norwegian Bone Marrow Donor
Registry (http:/www.nordonor.org/). The same control sample set
has been used in other studies [40]. Written informed consent was
obtained from all study participants. The study was approved by
The Regional Committee for Research Ethics.
Sub-classification of MG
The sub-classification of patients was done according to age at
onset and presence or absence of thymoma. EOMG was defined
as age at onset of 40 years or younger. Because of the uncertainty
as to where to set the age-cut off for LOMG, as previously
described by Aarli and colleagues [12], we classified MG with
onset over 40 years into two groups: an ‘‘intermediate group’’ with
age at onset of 41–59 years, and a late onset group (LOMG) with
age at onset of 60 years or older.
HLA Genotyping
Genomic DNA was extracted from peripheral blood lympho-
cytes using an in-house desalting method. HLA Class I (HLA-A, -
B, and -C) genotypes of the MG patients were resolved to
a consistent two-digit resolution level, and Class II (HLA-DRB1)
to a four-digit resolution level, using in-house sequencing-based
approaches. Ambiguities at DRB1 were resolved by selecting the
most probable genotype based on allele frequencies reported in
Caucasians (http://bioinformatics.nmdp.org/HLA). If the ambig-
uous genotypes had similar probabilities the genotype was assigned
as missing. The genotyping method used is described elsewhere
[41] and involves a polymerase chain reaction (PCR) amplification
using the PlatinumH Taq PCRx DNA polymerase kit (Invitrogen,
Carlsbad, CA, USA) followed by sequencing of exon 2 and 3 (for
Class I) and exon 2 (for Class II) using BigDyeH Terminator v3.1
chemistry (Applied Biosystems, Foster City, CA, USA) and an
ABI3730 capillary sequencer (Applied Biosystems). Primers and
protocols used for sequencing of the individual HLA loci are
available from the authors upon request. Allele assignment was
performed using Assigns SBTH v3.2.7b (Conexio Genomics,
Applecross, Australia) and the IMGT/HLA database v. 2.28.0
(http://www.ebi.ac.uk/imgt/hla/). HLA data for the healthy
controls were available from the Norwegian Bone Marrow Donor
Registry, and were at the same resolution level as the patients’.
HLA Class I and II Genes in Myasthenia Gravis
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36603
Statistical Analysis
Statistical analysis of genetic associations was performed using
UNPHASED v.2.404-w32 [42]. Rare alleles (n,2 in patients and
controls) were excluded. Conditional logistic regression (‘‘main
effects’’ test) was used to evaluate the dependency of the risk
contribution of the different loci HLA-A, -B, -C and -DRB1 in
EOMG in order to determine the most strongly associated locus.
The expectation maximization algorithm was used to estimate
maximum likelihood haplotype frequencies of B and DRB1 from
the genotypes at each locus, assuming Hardy-Weinberg equilib-
rium. The haplotype method [43] and the Svejgaard method [44]
Figure 1. Schematic overview of associated HLA alleles in MG. The HLA complex on chromosome 6 with its division into three classes. Some
key genes and their order on the chromosome are given. Associated HLA alleles reported earlier in Caucasian MG patients (see text for complete
references) are illustrated together with the results from the present study.
doi:10.1371/journal.pone.0036603.g001
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were used to assess which alleles and loci showed the primary
association and which appeared to be secondary due to LD.
Values for D’ and r2 were calculated for allele combination. Odds
ratios (OR) and 95% confidence intervals (CI) were calculated
with Woolf’s formula with Haldane’s correction for nominal p-
values (pnc). P-values ,0.01 after correction for number of
comparisons in the initial global locus tests (n = 4) were considered
significant. For allelic associations, novel associations were
corrected for number of comparisons before claiming significant
associations. Only the number of tested alleles at each locus were
corrected using Bonferroni correction (pc), as the alleles at HLA
loci do not fully represent independent tests due to the strong LD
(n = 8 for HLA-A, n = 21 for HLA-B, n = 13 for HLA-C and
n = 38 for HLA-DRB1). For alleles previously published to be
associated, uncorrected p-values (pnc) are also shown. When
assessing the strongest associations by conditional analyses, no
corrections were performed in order to avoid camouflaging weak
effects due to LD.
Results
A total of 369 Norwegian MG patients were successfully
genotyped for all four loci genotyped; 9 patients were excluded
due to missing genotypes and technical difficulties in genotyping.
The clinical characteristics of the MG cohort investigated are
shown in Table 1, and the associations between HLA loci and MG
subgroups are shown in Table 2. There were significant
associations of both the HLA Class I (HLA-A, -B and -C) loci
and the Class II (HLA-DRB1) locus in the EOMG group. LOMG
showed a strong association with only the DRB1 locus. No
significant associations were observed in any HLA loci in the
intermediate group (onset at 41–59 years) or to MG with
thymoma. The most frequent haplotype was AH 8.1 in both
EOMG (21%) and controls (9%), while HLA-A*02- or A*03-
B*07-C*07-DRB1*15:01 haplotype was most frequent in LOMG
(13%). An overview of allele frequencies in MG subgroups and
controls is available as supporting information in Table S1. The
clinical characteristics of MG patients carrying the most strongly
associated HLA genotypes reported in this study are shown in
Table S2 as supporting information.
LOMG
The DRB1 locus showed a strong association to LOMG
(pnc = 1.2.5610
26), while the B-locus was not associated
(pnc = 0.04). The strongest associated alleles in LOMG are shown
in Table 3, pointing to the DRB1*15:01 allele conferring the
strongest risk (OR 2.38, pnc = 2.0610
26, pc = 7.4610
25). In-
terestingly, other DR2 alleles, e.g. DRB1*15:02 were not
associated (pnc = 0.11). The DRB1*03:01 (pnc = 0.001, pc = 0.05)
and DRB1*13:01(pnc = 0.004, pc = 0.15) alleles showed modest
novel negative associations, however, when correcting for number
of comparisons (n = 38) in this analysis, these associations were no
longer significant, as also observed for the negative association
with B*08 (pnc = 0.003, pc = 0.07). The previously reported
association to HLA-B7 in LOMG was only weakly present in
our study (pnc = 0.01). Haplotype analysis of the DRB1*15:01
versus other HLA-B alleles showed the strongest LD with B*07
(D’ = 0.5, r2 = 0.2). This might explain the borderline association
found to B*07, and support that DRB1*15:01 is the superior risk
allele in LOMG. Sub-analysis of the nonthymomatous ATA
positive late onset MG patients over 40 years (n = 47) did not show
significant association with the DRB1*07:01 allele (pnc = 0.18).
In EOMG, positive associations were observed for the well-
established HLA-A*01, -B*08, -C*07 and -DRB1*0301 alleles
(Table 4). Conditional tests showed that virtually all associations at
the other loci disappeared when conditioning on either HLA-B or
-DRB1 (Table 5), indicating that these two loci are stronger
determinants than HLA-A and -C. In order to assess which of the
positively associated alleles at these two loci displayed the strongest
association, we performed a conditional haplotype analysis of
HLA-B*08 and -DRB1*03:01. Strong LD between the two alleles
was confirmed (D’ = 0.8, r2 = 0.7). HLA-B*08 was found to confer
risk to EOMG both when carried on the same haplotype as
DRB1*03:01 (p = 0.037) and in the absence of DRB1*03:01
(p = 0.005), while DRB1*03:01 was not associated after stratifying
the haplotypes according to B*08 (Table 6). Novel negative
associations were seen with HLA-A*02 (pnc = 4.6610
24,
pc = 3.7610
23), C*05 (pnc = 4.6610
23, pc = 0.06) and
DRB1*13:01(pnc = 3.1610
23, pc = 0.1), however, only A*02 was
significant associated after correction. This negative association of
the most common HLA-A allele could be explained by a reduction
in A*02 among patients expressing the protective A*01/B*08
haplotype. Hence, conditional haplotype analysis of HLA-A*02
and -B*08 was performed, and the results showed that HLA-A*02
did not confer significant protection when carried on the same
haplotype as B*08 (p = 0.51) nor did it do so when carried on
haplotypes without B*08 (p = 0.097) (data not shown).
To test whether the suggested negative association of HLA-
DRB1*13:01 found in both EOMG and LOMG could be
a general protective factor for MG, we pooled all MG subgroups
(except MG with thymoma) and compared the groups with
controls. This showed that the DRB1*13:01 allele was significantly
Table 1. Clinical characteristics of the Norwegian myasthenia gravis study cohort (n = 369).
MG subgroups
Total
n =369, n (%)
Female
n=229, n (%)
AChR-ab+
n=300, n (%)
Thymectomy
n=168, n (%)
Ocular MG1
n=68, n (%)
Immune-mediated
diseases2
n =110, n (%)
EOMG (#40) 154 (42) 131 (85) 116 (75) 108 (70) 20 (13) 49 (32)
MG with onset 41259
years
86 (23) 45 (52) 60 (70) 26 (30) 30 (35) 25 (29)
LOMG ($60) 99 (27) 39 (39) 94 (95) 5 (5) 16 (16) 31 (31)
Thymoma 30 (8) 14 (47) 30 (100) 29 (97) 3 (10) 5 (17)
1According to MGFA classification [39]: ocular MG (MGFA grade I), generalised MG (MGFA grade II-V), not available in 12 cases.
2Concomitant immune-mediated diseases include thyroid disease (hypo-, hyperthyroidsm, thyroiditis), type 1-diabetes, rheumatic diseases, systemic lupus
erythematosus (SLE), celiac disease, inflammatory bowel diseases (Crohns disease or ulcerative colitits). EOMG= early onset MG; LOMG= late onset MG; AChR-ab+ =
acetylcholine receptor-antibody positive.
doi:10.1371/journal.pone.0036603.t001
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associated with MG (OR 0.31, 95% CI 0.18–0.52,
pc = 4.71610
24). To elaborate on the results showing that B*08/
DRB1*03:01 are hazardous to EOMG and weakly protective to
LOMG, we compared the allele frequency of both alleles between
EOMG and LOMG subgroups. A significantly differential
distribution between EOMG and LOMG was seen for both
B*08 (pc = 2.95610
29), and also DRB1*03:01 (pc = 2.56610
25).
Discussion
We have investigated the HLA associations of Class I and Class
II alleles by performing comprehensive genotyping in a large and
representative Norwegian MG population, and explored potential
risk alleles in the different MG subgroups. Genetic differences
between EOMG and LOMG have been reported before, but our
study was able to define the primary risk alleles in EOMG and
LOMG to be HLA-B*08 and HLA-DRB1*15:01, respectively, in
our population. We also identified HLA-DRB1*13:01 as a general
MG protective allele that confers protection to both EOMG and
LOMG, a finding not reported before.
In LOMG, no genetic risk factors have been consistently
described previously, but associations with HLA- B7 and/or -DR2
and DR 7 have been reported [23,35]. A possible explanation for
the divergent results may be that the cut-off age at onset used for
LOMG has varied and that LOMG subgroups have been
heterogeneous [11,35]. By using age cut-off at 60 years for
LOMG in this study, as suggested also by others [15], we were
able to investigate a homogenous LOMG group. In doing so, we
identified a significant association to the HLA-DR2 allele
DRB1*15:01, which has not previously been reported by others.
This allele is known to be quite common in particular European
and Asian populations and is also the main genetic risk factor in
another autoimmune neurological disease, i.e. multiple sclerosis
[45]. It is, however, not known whether the occurrence of LOMG
is lower in other MG populations of African or Amerindian origin
where DRB1*15:01 is less frequent.
The DRB1 locus in LOMG has been examined in a previous
family-based study of a large French MG cohort, but neither of the
two DR2 alleles, DR15 or DR16, were found to be associated in
a subset of LOMG comprising predominantly of males with
normal thymus histopathology [35]. Instead, a subset of ATA
positive LOMG was significantly associated with HLA-DR7 and
negatively associated with DR3. This could not be reproduced in
the subset of ATA positive LOMG in our Norwegian MG cohort.
A borderline negative association of DRB1*03:01 was seen in the
overall group of LOMG in our cohort, but no association was
observed for DRB1*07:01. The lack of concordance between the
results from LOMG in our cohort and the French MG cohort may
be due partly to different inclusion criteria and genotyping
methods. Further, a population specific association to
DRB1*15:01 in the Norwegian MG population cannot be ruled
out.
Due to the limited number of MG with thymoma (n = 30), the
statistical power to detect the HLA-A association recently reported
by others [27] may have been too low in our study. Only 8% had
thymoma, which is lower than expected in a representative MG
population [10]. However, strong HLA associations have not been
reported in previous studies, and the susceptibility of MG patients
with thymoma may be more likely explained by a paraneoplastic
aetiology of the disorder [46].
For EOMG, the strongest predisposition observed in our
study was for the HLA-B*08 allele. Previous studies have
suggested the causative loci to be close to the Class III and
Class I region of the HLA complex, pointing out HLA-B as
a more superior risk locus than HLA-DRB1 [30,32]. However,
many of these studies were conducted at a time when genomic
HLA typing was not available, and the knowledge of the genetic
diversity of the HLA complex was more limited than today.
Table 2. The association between HLA loci and myasthenia gravis subgroups (p-values).
Locus EOMG n=154
MG with onset 41–59 years,
n = 86 LOMG ($60 years) n=99
Thymoma
n=30
HLA-A 2.161028 0.44 0.18 0.37
HLA-B 9.0610210 0.41 0.04 0.56
HLA-C 4.461025 0.21 0.77 0.92
HLA-DRB1 4.2610210 0.14 1.261026 0.49
EOMG=early onset MG, LOMG= late onset MG.
P-values are not corrected, p,0.01 is considered significant after correction for multiple comparisons (n = 4).
doi:10.1371/journal.pone.0036603.t002
Table 3. Associated alleles in late onset myasthenia gravis (LOMG).
Allele
Allele frequency
Cases n=99
Allele frequency
Controls n=651 OR 95% CI
Nominal
p-value
Bonferroni corrected
p-value
B*07 0.21 0.15 1.61 1.0421.90 0.01 0.21
B*08 0.06 0.13 0.42 0.2320.75 0.003 0.06
DRB1*03:01 0.05 0.13 0.35 0.1920.67 0.001 0.04
DRB1*13:01 0.01 0.07 0.22 0.0820.62 0.004 0.15
DRB1*15:01 0.26 0.13 2.38 1.6623.40 2.061026 7.661025
Odds Ratio (OR) and 95% confidence interval (CI) are shown for nominal p-values.
doi:10.1371/journal.pone.0036603.t003
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It was therefore important to readdress this in our large MG
study cohort using the higher resolution methods for HLA
genotyping. In spite of the strong LD on the extended HLA -
A1-B8-DR3 haplotype, we were able to map the primary HLA
association to the B*08 allele.
Our results underline a clear difference in the association of
B*08/DRB1*03:01 genotype between EOMG and LOMG,
especially between EOMG with age at onset below 40 years and
late onset MG with disease onset after 60 years. The intermediate
group of late onset MG with age at onset between 41–59 years
appears to be an overlapping group of MG, with a mixture of
EOMG and LOMG genetic risk factors. Based on these results, it
is still difficult to determine if the subset of LOMG with age of
onset 41–59 years belongs to an EOMG or a LOMG sub-
phenotype. This suggests that disease management and treatment
of these MG patients should still be evaluated individually, as also
implied by others [11,47].
The main strengths of our study are the large sample of EOMG
and LOMG patients from one population, extensive clinical
measures of the study cohort, and the use of comprehensive HLA
genotypin. However, there are also some limitations. As we did not
genotype the HLA-DQB1 and DQA1 loci, which are in strong LD
with the DRB1 locus, we cannot rule out that one of these (or in
fact other surrounding loci in LD) is the primary risk locus. Both
the haplotypes DRB*15:01- DQB1*06:02 and DRB*13:01-
DQB1*06:03 are inherited together in our Norwegian population,
which would hamper our ability to pinpoint the causal locus also
in the presence of full class II genotyping data. We also note that
the clinical characteristics of patients (e.g. thymus histopathology
and MGFA scores) were reported by different clinicians from the
collaborating neurological departments, and could have biased the
classification of subgroups. Further, the method used for
correcting p-values, using Bonferroni correction only within each
locus, may be too anti-conservative. However, due to the strong
LD between the loci, a more conservative method could over-
estimate p-values and camouflage novel associations. Therefore,
weak associations reported in this study need to be interpreted
with caution. Nevertheless, HLA-DRB1*13:01 was weakly nega-
tive associated with both EOMG and LOMG separately, but was
highly significant when the total MG population (excluding MG
with thymoma) was investigated. Because MG is a rare and also
a heterogeneous disease, low sample sizes of the different MG
subgroups have long hampered genetic studies of MG. Thus, for
future investigation of genetic risk factors in MG, collaborative
networks will be essential.
To the best of our knowledge, this study with comprehensive
genotyping of four HLA loci in MG is the first to provide detailed
HLA data in a large sample of MG patients comprising both
EOMG and LOMG subtypes. The HLA alleles also continue to
play a leading role in the genetic risk in other complex
autoimmune diseases such as type-1 diabetes, multiple sclerosis
and rheumatoid arthritis [18]. Even in the present time of
genome-wide association studies (GWAS), well-designed studies
dissecting the nature of the HLA associations in subgroups of MG
patients are much needed.
In conclusion, this study provides both novel and supporting
information of major HLA-associations in Caucasian MG. The
novelties of our findings are the identification of DRB1*15:01 as
Table 4. The most strongly associated HLA alleles in early onset myasthenia gravis (EOMG).
Allele
Allele frequency
Cases n=154
Allele frequency
Controls n=651 OR 95% CI
Nominal
p-value
Bonferroni corrected
p-value
A*01 0.31 0.16 2.43 1.8323.22 6.1610210 4.961029
A*02 0.24 0.35 0.60 0.4520.80 4.661024 3.761023
B*08 0.33 0.13 3.12 2.3024.20 1.2610214 2.5610213
C*07 0.47 0.32 1.90 1.4822.45 5.861027 7.561026
C*05 0.05 0.10 0.45 0.2620.78 4.661023 0.06
DRB1*03:01 0.31 0.13 2.90 2.1723.87 5.4610213 2.1610211
DRB1*07:01 0.03 0.09 0.39 0.2120.72 2.761023 0.10
DRB1*13:01 0.03 0.07 0.35 0.1720.70 3.161023 0.12
Odds Ratio (OR) and 95% confidence interval (CI) are shown for nominal p-values.
doi:10.1371/journal.pone.0036603.t004
Table 5. Conditional analyses of the HLA-A, -B, -C and DRB1
loci (p-values) in early onset myasthenia gravis (EOMG).
Conditional test HLA loci
Locus HLA-A HLA-B HLA-C HLA-DRB1
HLA-A 2 0.2 2.561025 0.08
HLA-B 2.061024 2 4.061024 0.05
HLA-C 9.061024 0.42 2 0.26
HLA-DRB1 2.061023 0.09 8.061023 2
P-values are not corrected, p,0.01 is considered significant after correction for
multiple comparisons (n = 4).
doi:10.1371/journal.pone.0036603.t005
Table 6. Assessment of the strongest association on the HLA-
B*08-DRB1*03:01 haplotype in early onset myasthenia gravis
(EOMG).
Comparison of haplotypes P-value OR 95% CI
Association of B*08+ vs. B*082 1.0610213 3.01 2.0124.02
Association of DRB1*03:01+ vs. DRB1*03:012 2.7610211 2.69 2.0123.60
Association of B*08 on DRB1*03:01+ 3.761022 2.15 1.0424.42
Association of B*08 on DRB1*03:012 2.561023 2.61 1.4024.87
Association of DRB1*03:01 on B*08+ 0.56 1.22 0.6322.36
Association of DRB1*03:01 on B*082 0.26 1.49 0.7522.95
+ = positives, 2 = negatives.
doi:10.1371/journal.pone.0036603.t006
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the strongest HLA risk allele in LOMG, and the finding of
DRB1*13:01 being a general protective allele for MG in our
population. Furthermore, HLA-B*08 was mapped to be the
primary risk allele in EOMG, underlining the distinct different
genetic HLA profile in EOMG and LOMG subgroups. This needs
to be taken into consideration in further studies investigating risk
factors in MG.
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Table S1 Allele frequencies in MG subgroups and
controls. Allele groups that include rare alleles are: HLA-A*09
(23, 24), A*10 (25, 26, 34, 66), A*19 (29, 30, 31, 32, 33), A*28 (68,
69), B*05 (51, 52), B*12 (44, 45), B*15 (62), B*16 (38, 39), B*17
(57, 58), B*21 (49, 50), B*22 (54, 55, 56), B*40 (60, 61).
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Table S2 Clinical characteristics of the MG study
cohort (n= 339) in relation to the most strongly associ-
ated HLA genotypes of this study. 1According to MGFA
classification [39]: ocular MG (MGFA grade I), generalised MG
(MGFA grade II-V), not available in 12 cases. 2Thymus
histopathology: hyperplasia or normal/atrophy, not available in
26 cases. 3Concomitant immune-mediated diseases in patients
include thyroid disease (hypo-, hyperthyroidsm, thyroiditis), type
1-diabetes, rheumatic diseases, systemic lupus erythematosus
(SLE), celiac disease, inflammatory bowel diseases (Crohns disease
or ulcerative colitits). *MG patients with thymoma (n = 30) were
excluded. 2 = positives, 2 = negatives.
(DOC)
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